Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status

Journal of Clinical Oncology

Volumn 24, Issue 4, 2006, Pages 675-680

  Vehmanen, Leena ^a   Elomaa, Inkeri ^a   Blomqvist, Carl ^a   Saarto, Tiina ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BONE DENSITY; BREAST CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; ADULT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 33644842287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.3515     Document Type: Article

References (28)

1. Ramaswamy B, Shapiro CL: Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30:763-775, 2003
2. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997
3. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001
4. Del Mastro L, Venturini M, Sertoli MR, et al: Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical implications. Breast Cancer Res Treat 43: 183-190, 1997
5. Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1:183-188, 1990
6. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996
7. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
8. Nabholtz J, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. 38th Annual Meeting of Am Soc Clin Oncol, Orlando, FL, May 18-21, 2002, (abstr 141)
9. Richards MA, O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester Trial. J Clin Oncol 8:2032-2039, 1990
10. Genant HK, Cann CE, Ettinger B, et al: Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699-705, 1982
11. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
12. Ward RL, Morgan G, Dalley D, et al: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22:87-94, 1993
13. Saarto T, Blomqvist C, Valimaki M, et al: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75:602-605, 1997
14. Marttunen MB, Hietanen P, Tiitinen A, et al: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:1158-1162, 1998
15. Grey AB, Stapleton JP, Evans MC, et al: The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636-641, 1995
16. Resch A, Biber E, Seifert M, et al: Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 37:661-664, 1998
17. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy pre-menopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
18. Sverrisdottir A, Fornander T, Jacobsson H, et al: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694-3699, 2004
19. Vehmanen L, Saarto T, Risteli J, et al: Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188, 2004
20. Nilsson CG, Lähteenmäki PL, Luukkainen T: Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 41:52-55, 1984
21. Vehmanen L, Saarto T, Elomaa I, et al: Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378, 2001
22. Ellmen J, Hakulinen P, Partanen A, et al: Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 82:103-111, 2003
23. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
24. O'Regan RM, Jordan VC: The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3:207-214, 2002
25. Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991
26. Feldmann S, Minne HW, Parvizi S, et al: Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 7:245-254, 1989
27. Sibonga JD, Evans GL, Hauck ER, et al: Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res Treat 41:71-79, 1996
28. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 45:1359-1368, 1999